Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

Bayer bags FDA nod for early prostate cancer drug darolutamide

Bayer bags FDA nod for early prostate cancer drug darolutamide

Now its approved, Nubeqa will go head-to-head in the non-metastatic CRPC market with J&J’s Erleada (apalutamide) – a follow-up to its Zytiga (abiraterone) brand which is ... Zytiga is only approved for metastatic CRPC and, as Xtandi and Erleada were

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics